DR. SAMUEL STROBER, M.D.
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA
License number
California G19834
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
2
300 Pasteur Dr, Palo Alto, CA 94305
405 Minoca Rd, Menlo Park, CA 94028
405 Minoca Rd, Menlo Park, CA 94028
Phone
(650) 723-6500
(650) 725-6104 (Fax)
(650) 725-6104 (Fax)
Organization information
See more information about SAMUEL STROBER at bizstanding.comSamuel Strober
300 Pasteur Dr, Palo Alto, CA 94305
Industry:
Medical Doctor's Office, Nonclassifiable Establishments, Offices and Clinics of Medical Doctors, Nsk
Executive:
Samuel So (Executive)
Samuel Strober MD
300 Pasteur Dr, Palo Alto, CA 94304
Industry:
Internist
Phone:
(650) 723-6500 (Phone)
Description:
There are 35 doctors at this site. Surgery is performed at this site.
Samuel Strober
Professional information
Samuel Strober, Palo Alto CA
Specialties:
Preventive Medicine, Internal Medicine, Clinical & Laboratory Immunology, Rheumatology, Immunopathology
Work:
Stanford Hospital and Clinics
300 Pasteur Dr, Palo Alto, CA 94304
300 Pasteur Dr, Palo Alto, CA 94304
Education:
Harvard University(1966)
Dr. Samuel Strober, Stanford CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
300 Pasteur Dr, Stanford 94305
(650) 723-6500 (Phone), (650) 725-8418 (Fax)
(650) 723-6500 (Phone), (650) 725-8418 (Fax)
Languages:
English, Spanish
Hospitals:
300 Pasteur Dr, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
Harvard Medical School
Graduated: 1966
Mass Gen Hospital
Stanford University Hospital
Harvard Medical School
Graduated: 1966
Mass Gen Hospital
Stanford University Hospital
Methods For Inhibition Of Polyclonal B Cell Activation And Immunoglobulin Class Switching To Pathogenic Autoantibodies By Blocking Cd1-Mediated Interactions
US Patent:
2001005, Dec 13, 2001
Filed:
Apr 27, 2001
Appl. No.:
09/844544
Inventors:
Defu Zeng - Palo Alto CA, US
Samuel Strober - Portola Valley CA, US
Samuel Strober - Portola Valley CA, US
International Classification:
A61K039/395
US Classification:
424/131100
Abstract:
Pathogenic polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies is inhibited by binding molecules that specifically interfere with CD1 antigen, but do not activate signaling (blocking agents), or by molecules that bind to the T cell antigen receptor on T cells that recognize CD1. When CD1 mediated signaling is thus blocked, the T cell response is diminished, resulting in reduced polyclonal B cell activation and reduced immunoglobulin class switching to pathogenic autoantibodies.
Methods For Inhibition Of Polyclonal B Cell Activation And Immunoglobulin Class Switching To Pathogenic Autoantibodies By Blocking Cd1-Mediated Interactions
US Patent:
2011003, Feb 17, 2011
Filed:
Apr 16, 2010
Appl. No.:
12/762091
Inventors:
Defu ZENG - Palo Alto CA, US
Samuel Strober - Portola Valley CA, US
Samuel Strober - Portola Valley CA, US
International Classification:
A61K 39/395, A61K 31/7028, A61K 31/661, A61K 38/02, A61P 37/02
US Classification:
4241331, 4241531, 4241421, 514 25, 514121, 514 11
Abstract:
Pathogenic polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies is inhibited by binding molecules that specifically interfere with CD1 antigen, but do not activate signaling (blocking agents), or by molecules that bind to the T cell antigen receptor on T cells that recognize CD1. When CD1 mediated signaling is thus blocked, the T cell response is diminished, resulting in reduced polyclonal B cell activation and reduced immunoglobulin class switching to pathogenic autoantibodies.
Enhancement Of Allogeneic Hematopoietic Stem Cell Transplantation
US Patent:
2012017, Jul 12, 2012
Filed:
Jan 10, 2012
Appl. No.:
13/347452
Inventors:
Samuel Strober - Stanford CA, US
Suparna Dutt - Palo Alto CA, US
Robert Lowsky - Stanford CA, US
Suparna Dutt - Palo Alto CA, US
Robert Lowsky - Stanford CA, US
International Classification:
A61K 35/12, A61P 35/02, A61P 35/00
US Classification:
424 9371
Abstract:
Methods and compositions are provided to augment the conversion of mixed hematopoietic cell chimerism to complete donor cell chimerism following allogeneic hematopoietic cell transplantation (HCT), where such transplantation may be utilized for treatment of cancer such as leukemia and lymphoma or for other conditions requiring reconstitution of the hematopoietic system, e.g. treatment of anemias, thalassemias, autoimmune conditions, and the like. The present invention improves on conventional DLI by utilizing a composition of substantially purified donor memory CD8 T cells as DLI following allogeneic HCT, where the cells are administered at a suitable time following transplantation. The methods provide for a more complete donor chimerism, and have the further benefit of killing tumor cells without GVHD. The memory CD8+ T cells may include one or both of central and effector memory T cells, usually both.
Methods For Inhibition Of Nkt Cells
US Patent:
2010019, Aug 5, 2010
Filed:
Feb 1, 2010
Appl. No.:
12/697882
Inventors:
Samuel Strober - Stanford CA, US
Everett Hurteau Meyer - Redwood City CA, US
Dale T. Umetsu - Newton MA, US
Everett Hurteau Meyer - Redwood City CA, US
Dale T. Umetsu - Newton MA, US
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY - PALO ALTO CA
International Classification:
A61K 31/7032, A61P 37/08, A61P 11/06, C12Q 1/02
US Classification:
514 25, 435 29
Abstract:
Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example β-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.
Biomarkers For Determining An Allograft Tolerant Phenotype
US Patent:
2012032, Dec 27, 2012
Filed:
Dec 1, 2010
Appl. No.:
13/512539
Inventors:
Minnie M. Sarwal - Portola Valley CA, US
Li Li - Fremont CA, US
Samuel Strober - Stanford CA, US
Li Li - Fremont CA, US
Samuel Strober - Stanford CA, US
International Classification:
C40B 30/04, C40B 40/06, C40B 40/10, C12Q 1/68
US Classification:
506 9, 435 611, 435 612, 506 16, 506 18, 435 792, 436501
Abstract:
Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression level of one or more gene in a sample from the subject, e.g., a blood sample, is assayed to obtain a gene expression result, where the gene expression result includes a result for a biomarker of graft tolerance. The obtained gene expression result is then employed to determine whether the subject has a graft tolerant phenotype. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen.
Suppressor And Progenitor Cells
US Patent:
5985656, Nov 16, 1999
Filed:
Nov 4, 1992
Appl. No.:
7/971723
Inventors:
Samuel S. Strober - Portola Valley CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
C12N 508
US Classification:
435325
Abstract:
Natural suppressor (NS) cells secrete a soluble protein suppressor factor (SF) which suppresses the mixed lymphocyte response. NS cells as described herein are null, i. e. , have the phenotype IL-2R. sup. +, CD3. sup. -, CD4. sup. -, CD8. sup. -, TCR. alpha. beta. sup. -, Ig. sup. -, MAC-1. sup. -, or are double negative suppressors (DNS); i. e. , have the phenotype IL-2R. sup. +, CD3. sup. +, CD4. sup. -, CD8. sup. -, TCR. alpha. beta. sup. +. Both NS and SF are useful in vivo to confer immunotolerance with respect to allogeneic transplants, and to effect immunosuppression. They also enhance engraftment of transplanted cells. A population of cells can be provided using density gradient separation techniques which is enriched in progenitor cells as identified by the presence of CD34 surface markers.
Methods For Inhibition Of Nkt Cells
US Patent:
7682614, Mar 23, 2010
Filed:
Nov 2, 2005
Appl. No.:
11/266033
Inventors:
Samuel Strober - Stanford CA, US
Everett Hurteau Meyer - Redwood City CA, US
Dale T. Umetsu - Newton MA, US
Everett Hurteau Meyer - Redwood City CA, US
Dale T. Umetsu - Newton MA, US
Assignee:
The Board Of Trustees Of The Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 31/7028, A61K 39/395
US Classification:
4241441, 4241531, 514 25
Abstract:
Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example β-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.
Tumor Vaccination In Combination With Hematopoietic Cell Transplantation For Cancer Therapy
US Patent:
8506954, Aug 13, 2013
Filed:
Dec 1, 2009
Appl. No.:
12/592752
Inventors:
Samuel Strober - Portola Valley CA, US
Alexander Filatenkov - Menlo Park CA, US
Alexander Filatenkov - Menlo Park CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39/00, A61N 5/10
US Classification:
424 937, 424 9371, 4242771, 378 65
Abstract:
In one aspect, the present invention provides a method for treating cancer comprising tumor cell vaccination in combination with hematopoietic and immune cell transplantation. In some embodiments, the method involves autologous tumor cell vaccination prior to autologous hematopoietic and immune cell transplantation. In another aspect, the present invention provides a method of purifying tumor cells from a subject in preparation for vaccination.